According to the latest report by IMARC Group, titled “Biosimilar Market in Europe: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the biosimilar market in Europe size reached US$ 9,841 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 35,993 Million by 2028, exhibiting a growth rate (CAGR) of 20.41% during 2023-2028.
Biosimilars are biological medicines that are highly like reference biologic products in terms of quality, safety, and efficacy. These complex medications are developed to be highly similar but not identical to the original reference biologics, which are approved through a rigorous regulatory process. Biosimilars are produced using living organisms or derived from living cells, and they mimic the structure and function of the reference biologics. They offer a more affordable alternative to costly biologic drugs while maintaining similar therapeutic effects. Biosimilars undergo extensive testing and demonstrate a comparable safety and efficacy profile to the reference biologic, ensuring they are suitable for treating various medical conditions.
Request for a PDF sample of this report: https://www.imarcgroup.com/europe-biosimilar-market/requestsample
Europe Biosimilar Market Trends:
The rising prevalence of chronic diseases and the increasing demand for cost-effective treatments are driving the adoption of biosimilars in Europe. Moreover, biosimilars offer an opportunity to address the growing healthcare burden by providing more affordable alternatives to expensive biologic drugs. The cost savings associated with biosimilars allow healthcare systems to allocate resources efficiently and expand patient access to critical therapies. Supportive regulatory frameworks and guidelines in Europe are facilitating the development and commercialization of biosimilars.
The European Medicines Agency (EMA) has established robust regulatory pathways for biosimilars, ensuring stringent requirements for their approval. This regulatory clarity and the established biosimilar approval process have encouraged the entry of biosimilar manufacturers into the European market, fostering competition and market growth. Furthermore, the expiry of patents for several biologic drugs in Europe is opening opportunities for biosimilar manufacturers to enter the market and offer affordable alternatives. The patent expiration allows for increased competition, leading to market growth and expanded access to biosimilars. The Europe biosimilar market is poised for continued growth as stakeholders recognize the value of biosimilars in improving patient access to high-quality, affordable therapies and driving cost efficiencies in healthcare delivery.
Europe Biosimilar Market 2023-2028 Competitive Analysis and Segmentation:
Competitive Landscape With Key Players:
The competitive landscape of the biosimilar market in Europe has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these Key Players Include:
- Novartis
- Pfizer
- Teva
- Celltrion
- Samsung Bioepis
- Amgen
- Apotex
- Ratiopharm
- Mylan
- Merck Sharp & Dohme
- Eli Lilly
- Accord Healthcare Ltd
- Boehringer Ingelheim
- Hexal Ag
- Stada Arzneimittel Ag
Key Market Segmentation:
Breakup by Country:
- Italy
- Germany
- United Kingdom
- France
- Spain
- Rest of Europe
Breakup by Molecule:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
- Adalimumab
Breakup by Indication:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
Breakup by Manufacturing Type:
- In-house Manufacturing
- Contract Manufacturing
Ask Analyst for Customization and Explore full report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=1023&flag=E
Key Highlights of the Report:
- Market Performance (2017-2022)
- Market Outlook (2023- 2028)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St
Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800
